Inozyme Pharma Inc (INZY) — Financial Flexibility Index
Inozyme Pharma Inc (INZY) has a Financial Flexibility Index of -0.46x as of March 2025. Free cash flow of $-29.15 Million (operating CF $-29.15 Million minus capex $0.00) represents 0% of total liabilities ($63.37 Million). Check Inozyme Pharma Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inozyme Pharma Inc Financial Flexibility Index (2018–2024)
Historical Financial Flexibility Index trend for Inozyme Pharma Inc across 7 annual periods. See Inozyme Pharma Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Inozyme Pharma Inc (2018–2024)
Year-by-year free cash flow to debt coverage for Inozyme Pharma Inc. For the full company profile including market capitalisation, see INZY company net worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.41x | $-91.84 Million | $-91.91 Million | $65.36 Million | ▼ -20.5% |
| 2023 | -1.17x | $-70.38 Million | $-70.67 Million | $60.37 Million | ▲ +57.7% |
| 2022 | -2.76x | $-57.35 Million | $-57.76 Million | $20.80 Million | ▲ +17.6% |
| 2021 | -3.35x | $-47.76 Million | $-48.15 Million | $14.27 Million | ▼ -6.4% |
| 2020 | -3.14x | $-35.41 Million | $-35.97 Million | $11.26 Million | ▼ -1266.9% |
| 2019 | -0.23x | $-18.67 Million | $-18.81 Million | $81.16 Million | ▼ -43.9% |
| 2018 | -0.16x | $-9.18 Million | $-9.44 Million | $57.42 Million | — |